Search results for "Lua"

showing 10 items of 3286 documents

Goldmann Applanation Tonometry Using Sterile Disposable Silicone Tonometer Shields

1996

Abstract Purpose: Placement of a sterile single-use cover over the tonometer tip may be a convenient and safe alternative method to repeated chemical disinfection. This study was undertaken to evaluate the accuracy and performance of Goldmann applanation tonometry using a sterile disposable silicone tonometer shield over the biprism tip. Methods: The same investigator measured intraocular pressure in 120 eyes with and without the shield. The eyes were tested randomly first with either the uncovered or the covered tonometer to control for the possible effects of repeated tonometry influencing measurement differences. Readings were recorded independently in a masked fashion. Results: The intr…

AdultMaleApplanation tonometryIntraocular pressuremedicine.medical_specialtyAdolescentgenetic structuresSiliconesOcular hypertensionGlaucomaSensitivity and SpecificityGoldmann applanation tonometryChemical disinfectionTonometry Ocularchemistry.chemical_compoundSiliconeDouble-Blind MethodOphthalmologymedicineHumansChildDisposable EquipmentIntraocular PressureAgedAged 80 and overAlternative methodsbusiness.industryReproducibility of ResultsGlaucomaMiddle Agedmedicine.diseaseeye diseasesSurgeryOphthalmologychemistryEvaluation Studies as TopicInfertilityFemaleOcular Hypertensionsense organsbusinessOphthalmology
researchProduct

The moderator effect of sex on attitude toward communication, emotional intelligence, and empathy in the nursing field

2017

Objectives: to analyze differences in the variables for the object of this study (attitude toward communication, emotional intelligence, and empathy) according to sex; verify correlations among variables between men and women and analyze regression models according to sex. Method: the ATC was used to measure attitudes toward communication; the Jefferson Scale of Empathy was used to measure empathy; and the Trait Meta Mood Scale 24 was used to measure emotional intelligence. The sample was composed of 450 nurses working in 7 hospitals located in Valencia, Spain. The t-test for independent samples was used to verify whether there were statistically significant differences, together with a pri…

AdultMaleAttitude of Health PersonnelNursingSexoValoración de enfermeríaCorrelaçõesInteligência EmocionalYoung Adult03 medical and health sciencesSex Factors0302 clinical medicineApreciación de la actuaciónHumans030212 general & internal medicineAttitudes Towards CommunicationEmotional IntelligenceServicio de enfermeríalcsh:RT1-120lcsh:NursingCorrelationsEvaluación030504 nursingCommunicationConductaEnfermagemAtitudes em Relação à ComunicaçãoMiddle AgedEmpatiaFemaleOriginal ArticleSexEmpathy0305 other medical scienceRevista Latino-Americana de Enfermagem
researchProduct

Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: Comparison with α-fetoprotein

1998

This study evaluated the significance of serum pancreatitis-associated protein (PAP) assay, as a marker of hepatocellular carcinoma (HCC), in comparison and combined with α-fetoprotein (AFP) assay. Sixty-five patients with HCC, 59 with liver cirrhosis (LC) and 68 asymptomatic controls (C) were studied. PAP and AFP values significantly increased from C to LC and HCC group (p < 0.0001). The area under receiver-operating characteristic (ROC) curve for the two markers was not statistically different. At 100% specificity, ROC analysis gave a cut-off level for AFP of 166 IU/l with 40% sensitivity, and a cut-off level of 240 µg/l for PAP with 23% sensitivity. Diagnostic accuracy of combined AFP…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyCirrhosisCarcinoma HepatocellularPancreatitis-Associated ProteinsAsymptomaticSensitivity and SpecificityAntigens NeoplasmBiomarkers TumorMedicineHumansLectins C-TypeneoplasmsTumor markerAgedbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesLogistic ModelsOncologyHepatocellular carcinomaPancreatitisFemalealpha-Fetoproteinsmedicine.symptombusinessClinical evaluationSerum markersAcute-Phase Proteins
researchProduct

Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.

2000

BACKGROUND Making a morphologic distinction between benign and malignant melanocytic tumors of the skin is frequently difficult, especially because “gray zones” between these lesions often exist. DNA image cytometry as an adjuvant method for the diagnosis and prognostic prediction of premalignant lesions and malignant tumors of many other organs is already well established. The aim of this study was to determine whether DNA image cytometry is helpful in distinguishing benign from malignant melanocytic lesions and whether cytometry would give valid information with which to predict the prognoses associated with malignant melanomas. METHODS DNA image cytometry was performed on 127 benign and …

AdultMaleCancer ResearchPathologymedicine.medical_specialtySkin NeoplasmsStatistics as TopicVideo RecordingMalignant transformationBreslow ThicknessHutchinson's Melanotic FreckleNevus BlueNevus Epithelioid and Spindle CellmedicineHumansMelanomaNevusDNA Image CytometryImage CytometryRetrospective StudiesPloidiesbusiness.industryMelanomaCancerReproducibility of ResultsDNA NeoplasmMiddle Agedmedicine.diseaseAneuploidyPrognosisDiploidyHMB-45OncologyEvaluation Studies as TopicImage CytometryMelanocytesFemalebusinessCytometryDysplastic Nevus SyndromePrecancerous ConditionsFollow-Up StudiesForecastingCancer
researchProduct

Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma.

1992

A phase II trial of citrovorum factor, 500 mg/m2/week, plus 5-fluorouracil, 400 mg/m2/week on day 1, and cisplatin, 20 mg/m2/week on day 2, was carried out in a group of 40 patients with metastatic colorectal carcinoma. A partial response with a mean duration of 8.4+ months was achieved in 24% of patients, a minimal response with a mean duration of 5.4 months was obtained in 6% of patients, and a stabilization of 6.2 months was achieved in 41%. Ten patients (29%) progressed. A 38% partial response rate was seen in patients with advanced rectal carcinoma, whereas no response was obtained in patients with colon cancer. Interestingly, 5 partial responses were seen in 12 patients pretreated wit…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerCitrovorum factorLeucovorinGastroenterologyDrug Administration ScheduleInternal medicinePartial responseRectal carcinomaAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansIn patientAgedCisplatinbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgeryOncologyFluorouracilDrug EvaluationFemaleFluorouracilCisplatinbusinessColorectal Neoplasmsmedicine.drugCancer investigation
researchProduct

Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Color…

2004

BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC). METHODS A total of 140 patients received capecitabine at a dose of 1250 mg/m2 twice daily on Days 2–15 and irinotecan at a dose of either 300 mg/m2 on Day 1 (Arm A) or 150 mg/m2 on Days 1 and 8 (Arm B) every 3 weeks. During the course of the study, enrollment was continued using lower doses of capecitabine (1000 mg/m2 twice daily) and irinotecan (Arm A: 240 mg/m2; Arm B: 120 mg/m2) to improve the safety profile of the combinations. RESULTS Efficacy was evaluable in 134 patients (68 in…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerPhases of clinical researchCOLON CANCERIrinotecanGastroenterologyDeoxycytidineDrug Administration Schedulecolorectal carcinoma first-line treatment irinotecan and capecitabine combination Phase II triallaw.inventionCapecitabineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAdverse effectCapecitabineAgedXELIRIbusiness.industryCarcinomaCancerMiddle Agedmedicine.diseaseSurgeryIrinotecanOncologyDrug EvaluationCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drug
researchProduct

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.

1989

The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. Patients were treated at four different dose levels (120 to 1,000 micrograms/m2/d) by either daily intravenous (IV) bolus injection or 24-hour continuous infusion. Administration of rh GM-CSF resulted in a broad spectrum of dose- and schedule-dependent hematopoietic effects. Sustained infusion of rh GM-CSF elicited a maximum 17-fold average peak increase of the total WBC count with mainly neutrophils, eosinophils, and monocytes accounting for this rise, and increases in bone marrow cellularity with a…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentMicrogramMalignancyDrug Administration ScheduleLeukocyte CountColony-Stimulating FactorsIn vivoBone MarrowInternal medicineNeoplasmsmedicineHumansPlateletLeukocytosisGrowth SubstancesInfusions IntravenousAgedbusiness.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorMiddle Agedmedicine.diseaseRecombinant ProteinsHematopoiesisHaematopoiesisEndocrinologyGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncologyImmunologyInjections IntravenousDrug EvaluationFemalemedicine.symptombusinessmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.

1990

Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated with oral tegafur (TG) 1,000 mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable patients seven patients had a partial response (PR. 17%) with a median duration of 20.5 weeks, three had a minimal response (7%) with a median duration of 23.7 weeks, nine showed a stabilisation which lasted a median of 31.3 weeks, and 23 progressed (55%). No response was obtained in patients affected by carcinoma of the pancreas and the hepatobiliary system. All PRs were achieved in patients with metastatic disease to the liver. No response was seen in patients with bone, lung or noda…

AdultMaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentPhases of clinical researchAdministration OralTegafurGastroenterologyStomach NeoplasmsInternal medicinemedicineCarcinomaHumansAgedTegafurChemotherapyGastrointestinal tractbusiness.industryStomachMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureOncologyVomitingDrug EvaluationFemalemedicine.symptombusinessColorectal Neoplasmsmedicine.drugResearch ArticleBritish Journal of Cancer
researchProduct

Clinical application of a new rheolytic thrombectomy catheter system for massive pulmonary embolism

1999

AdultMaleCardiac Catheterizationmedicine.medical_specialtyPulmonary ArterymedicineHumansRadiology Nuclear Medicine and imagingIntensive care medicineAgedThrombectomybusiness.industryCoronary ThrombosisHemodynamicsGeneral MedicineMiddle Agedmedicine.diseasePulmonary embolismRadiographyCatheterEmbolismEvaluation Studies as TopicFemaleRadiologyPulmonary EmbolismRheologyCardiology and Cardiovascular MedicinebusinessCatheterization and Cardiovascular Interventions
researchProduct